Aktis Oncology (AKTS.US) Debuts on Nasdaq Tonight with IPO Priced at $18 Per Share

Stock News01-09

Aktis Oncology (AKTS.US), a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors, is set to list on the Nasdaq tonight. The company raised $318 million by offering 17.7 million shares at $18 per share, which is at the high end of its $16 to $18 price range. Initially planning to offer 11.8 million shares within the same price range, the company expanded the offering size on Wednesday. Partner Eli Lilly (LLY.US) has indicated it will purchase $100 million worth of stock in the offering. Following the pricing, Aktis Oncology's fully diluted market valuation reaches $1 billion.

Aktis Oncology is a clinical-stage oncology company dedicated to developing alpha-particle radiopharmaceuticals for common solid tumors. Its development pipeline includes: Ac-AKY-1189 for Nectin-4 expressing cancers, currently in a multi-center U.S. Phase 1b clinical trial that has enrolled approximately 150 patients, with preliminary results expected in the first quarter of 2027; and Ac-AKY-2519 for B7-H3 expressing tumors, with an Investigational New Drug (IND) application planned for submission in 2026. Furthermore, the company manages multiple domestic and international isotope supply partnerships, an internally invested cGMP facility expected to be operational by 2026, and discovery-stage collaborations with partners to advance additional miniprotein radioconjugate programs. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are acting as joint book-running managers for the offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190068686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190068686","market":"sh","top_or_hot":-1,"title":"Aktis Oncology (AKTS.US) Debuts on Nasdaq Tonight with IPO Priced at $18 Per Share","media":"Stock News","content":"<p>Aktis Oncology (AKTS.US), a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors, is set to list on the Nasdaq tonight. The company raised $318 million by offering 17.7 million shares at $18 per share, which is at the high end of its $16 to $18 price range. Initially planning to offer 11.8 million shares within the same price range, the company expanded the offering size on Wednesday. Partner Eli Lilly (LLY.US) has indicated it will purchase $100 million worth of stock in the offering. Following the pricing, Aktis Oncology's fully diluted market valuation reaches $1 billion.</p>\n<p>Aktis Oncology is a clinical-stage oncology company dedicated to developing alpha-particle radiopharmaceuticals for common solid tumors. Its development pipeline includes: Ac-AKY-1189 for Nectin-4 expressing cancers, currently in a multi-center U.S. Phase 1b clinical trial that has enrolled approximately 150 patients, with preliminary results expected in the first quarter of 2027; and Ac-AKY-2519 for B7-H3 expressing tumors, with an Investigational New Drug (IND) application planned for submission in 2026. Furthermore, the company manages multiple domestic and international isotope supply partnerships, an internally invested cGMP facility expected to be operational by 2026, and discovery-stage collaborations with partners to advance additional miniprotein radioconjugate programs. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are acting as joint book-running managers for the offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aktis Oncology (AKTS.US) Debuts on Nasdaq Tonight with IPO Priced at $18 Per Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAktis Oncology (AKTS.US) Debuts on Nasdaq Tonight with IPO Priced at $18 Per Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-09 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aktis Oncology (AKTS.US), a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors, is set to list on the Nasdaq tonight. The company raised $318 million by offering 17.7 million shares at $18 per share, which is at the high end of its $16 to $18 price range. Initially planning to offer 11.8 million shares within the same price range, the company expanded the offering size on Wednesday. Partner Eli Lilly (LLY.US) has indicated it will purchase $100 million worth of stock in the offering. Following the pricing, Aktis Oncology's fully diluted market valuation reaches $1 billion.</p>\n<p>Aktis Oncology is a clinical-stage oncology company dedicated to developing alpha-particle radiopharmaceuticals for common solid tumors. Its development pipeline includes: Ac-AKY-1189 for Nectin-4 expressing cancers, currently in a multi-center U.S. Phase 1b clinical trial that has enrolled approximately 150 patients, with preliminary results expected in the first quarter of 2027; and Ac-AKY-2519 for B7-H3 expressing tumors, with an Investigational New Drug (IND) application planned for submission in 2026. Furthermore, the company manages multiple domestic and international isotope supply partnerships, an internally invested cGMP facility expected to be operational by 2026, and discovery-stage collaborations with partners to advance additional miniprotein radioconjugate programs. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are acting as joint book-running managers for the offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKTS","symbol_name":"Aktis Oncology","start_time":0,"source_url":"","article_id":"1190068686","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190068686","pubTimestamp":1767949068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Aktis Oncology (AKTS.US), a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors, is set to list on the Nasdaq tonight. The company raised $318...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKTS":"Aktis Oncology","USAW.SI":"AMZN 3xLongSG261006","BK1147":"投资银行业与经纪业","USJW.SI":"ALPHAB 3xLongSG261006","QID":"两倍做空纳斯达克指数ETF-ProShares","BK4148":"电子元件","TSYW.SI":"TESLA 3xLongSG261006","TQQQ":"纳指三倍做多ETF","BK4007":"制药","PSQ":"做空纳斯达克100指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","NVIW.SI":"NVDA 3xLongSG261006"},"translate_title":"Aktis Oncology(AKTS.US)今晚在纳斯达克上市，IPO定价为每股18美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKTS":1,"USAW.SI":1,"NVIW.SI":1,"QQQ":1,"TSYW.SI":1,"QLD":1,"TQQQ":1,"SQQQ":1,"MNQmain":1,"PSQ":1,"USJW.SI":1,"QID":1},"content_text":"Aktis Oncology (AKTS.US), a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for solid tumors, is set to list on the Nasdaq tonight. The company raised $318 million by offering 17.7 million shares at $18 per share, which is at the high end of its $16 to $18 price range. Initially planning to offer 11.8 million shares within the same price range, the company expanded the offering size on Wednesday. Partner Eli Lilly (LLY.US) has indicated it will purchase $100 million worth of stock in the offering. Following the pricing, Aktis Oncology's fully diluted market valuation reaches $1 billion.\nAktis Oncology is a clinical-stage oncology company dedicated to developing alpha-particle radiopharmaceuticals for common solid tumors. Its development pipeline includes: Ac-AKY-1189 for Nectin-4 expressing cancers, currently in a multi-center U.S. Phase 1b clinical trial that has enrolled approximately 150 patients, with preliminary results expected in the first quarter of 2027; and Ac-AKY-2519 for B7-H3 expressing tumors, with an Investigational New Drug (IND) application planned for submission in 2026. Furthermore, the company manages multiple domestic and international isotope supply partnerships, an internally invested cGMP facility expected to be operational by 2026, and discovery-stage collaborations with partners to advance additional miniprotein radioconjugate programs. J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are acting as joint book-running managers for the offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190068686","isCrawlerRequest":true}